Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
Abstract Background First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with immune checkpoint inhibitors (ICIs). However, phase III studies of combinations of cytotoxic chemotherapy and ICIs have included on...
Main Authors: | Yoshimasa Shiraishi, Junji Kishimoto, Takayuki Shimose, Yukihiro Toi, Shunichi Sugawara, Isamu Okamoto |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-022-10056-x |
Similar Items
-
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer
by: Himani Aggarwal, et al.
Published: (2023-01-01) -
Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
by: Jun Sugisaka, et al.
Published: (2023-11-01) -
Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report
by: Rei Tsutsumi, et al.
Published: (2022-07-01) -
Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
by: Hisao Imai, et al.
Published: (2023-09-01) -
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study
by: Likun Chen, et al.
Published: (2023-11-01)